• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[作为儿科和青少年风湿病学会以及德国风湿病学会“对秋水仙碱反应不足或不耐受的家族性地中海热患者的循证治疗建议”依据的系统文献检索结果]

[Results of the systematic literature search as basis for the "Evidence-based treatment recommendations for familial Mediterranean fever patients with insufficient response or intolerability to colchicine" of the Society for Pediatric and Adolescent Rheumatology and the German Society for Rheumatology].

作者信息

Sahr T, Kiltz U, Weseloh C, Kallinich T, Braun J

机构信息

Rheumazentrum Ruhrgebiet, Herne, Ruhr-Universität Bochum, Claudiusstr. 45, 44649, Herne, Deutschland.

Deutsche Gesellschaft für Rheumatologie, Berlin, Deutschland.

出版信息

Z Rheumatol. 2020 Nov;79(9):943-951. doi: 10.1007/s00393-020-00886-0. Epub 2020 Sep 30.

DOI:10.1007/s00393-020-00886-0
PMID:32997267
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7647992/
Abstract

BACKGROUND

Familial Mediterranean fever (FMF) is a genetic disease of childhood and adulthood which is relatively rare in Germany. It is characterized by recurrent febrile attacks, peritonitis, pleuritis and arthritis. The established treatment with colchicine is effective and well-tolerated by most patients; however, some patients do not adequately respond or do not tolerate this treatment. Biologics can be considered for some of these patients. The Society for Pediatric and Adolescent Rheumatology (GKJR) and the German Society for Rheumatology (DGRh) have agreed to develop joint recommendations for this specific clinical situation.

AIM

Implementation of a systematic literature search (SLR) on the basis of the EULAR recommendations published in 2016 as the foundation for the development of evidence-based treatment recommendations for FMF patients with insufficient response or intolerance to colchicine.

METHODS

The SLR was performed using references from various databases as an update of the SLR carried out by EULAR up to 2014, whereby all articles must have been published between 1 January 2015 and 31 December 2017. The Rayyan abstract tool for the preselection and the classification of the Oxford Centre for Evidence Based Medicine 2009 were used for the preparation of the evidence tables.

RESULTS

The search yielded 360 hits and after duplicate matching 263. A total of 88 publications were included (34%) and 102 excluded (39%), a review of the full publication was necessary for a further 73 (28%) and 43 were discussed more intensively. Finally, 64 publications (24%) remained. A total of 4 case-control studies, 31 cohort studies, 8 case series, 7 controlled studies (including 5 abstracts), 10 reviews, 4 meta-analyses and systematic reviews were accepted.

DISCUSSION

The SLR was carried out in a scientifically accurate and transparent manner according to international standards. The SLR proved to be a good basis for a consensus on the 5 overarching principles and the 10 recommendations, so that the joint activity of the GKJR and DGRh was successfully and even promptly concluded. The recommendations are a solid basis for treating patients of all ages with FMF. The explanations on the problem of colchicine resistance play an important role here.

摘要

背景

家族性地中海热(FMF)是一种儿童和成人期的遗传性疾病,在德国相对罕见。其特征为反复发热发作、腹膜炎、胸膜炎和关节炎。秋水仙碱的既定治疗方法有效且大多数患者耐受性良好;然而,一些患者对此治疗反应不佳或不耐受。对于其中一些患者可考虑使用生物制剂。儿童和青少年风湿病学会(GKJR)和德国风湿病学会(DGRh)已同意针对这一特定临床情况制定联合建议。

目的

基于2016年发表的欧洲抗风湿病联盟(EULAR)建议进行系统文献检索(SLR),作为为对秋水仙碱反应不足或不耐受的FMF患者制定循证治疗建议的基础。

方法

SLR使用来自各种数据库的参考文献,作为EULAR截至2014年进行的SLR的更新,所有文章必须发表于2015年1月1日至2017年12月31日之间。使用Rayyan摘要工具进行预选,并采用牛津循证医学中心2009年的分类方法来编制证据表。

结果

检索共获得360条结果,重复匹配后为263条。共纳入88篇出版物(34%),排除102篇(39%),另外73篇(28%)需要对全文进行审查,43篇进行了更深入的讨论。最后,剩下64篇出版物(24%)。共接受4项病例对照研究、31项队列研究、8个病例系列、7项对照研究(包括5篇摘要)、10篇综述、4项荟萃分析和系统评价。

讨论

SLR按照国际标准以科学准确和透明的方式进行。SLR被证明是就5项总体原则和10项建议达成共识的良好基础,因此GKJR和DGRh的联合活动得以成功甚至迅速完成。这些建议是治疗各年龄段FMF患者的坚实基础。关于秋水仙碱耐药问题的解释在此起着重要作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e407/7647992/4d9793a66ab7/393_2020_886_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e407/7647992/4d9793a66ab7/393_2020_886_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e407/7647992/4d9793a66ab7/393_2020_886_Fig1_HTML.jpg

相似文献

1
[Results of the systematic literature search as basis for the "Evidence-based treatment recommendations for familial Mediterranean fever patients with insufficient response or intolerability to colchicine" of the Society for Pediatric and Adolescent Rheumatology and the German Society for Rheumatology].[作为儿科和青少年风湿病学会以及德国风湿病学会“对秋水仙碱反应不足或不耐受的家族性地中海热患者的循证治疗建议”依据的系统文献检索结果]
Z Rheumatol. 2020 Nov;79(9):943-951. doi: 10.1007/s00393-020-00886-0. Epub 2020 Sep 30.
2
[Evidence-based treatment recommendations for familial Mediterranean fever : A joint statement by the Society for Pediatric and Adolescent Rheumatology and the German Society for Rheumatology].[家族性地中海热的循证治疗建议:儿科与青少年风湿病学会和德国风湿病学会联合声明]
Z Rheumatol. 2019 Feb;78(1):91-101. doi: 10.1007/s00393-018-0588-1.
3
Treat-to-target strategies for the management of familial Mediterranean Fever in children.针对儿童家族性地中海热的靶向治疗策略。
Pediatr Rheumatol Online J. 2023 Sep 26;21(1):108. doi: 10.1186/s12969-023-00875-y.
4
Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.抗白细胞介素-1 治疗对秋水仙碱抵抗型家族性地中海热患儿生活质量的影响:单中心经验。
Int J Rheum Dis. 2020 Jul;23(7):977-981. doi: 10.1111/1756-185X.13891. Epub 2020 Jun 18.
5
Interventions for reducing inflammation in familial Mediterranean fever.降低家族性地中海热炎症的干预措施。
Cochrane Database Syst Rev. 2018 Oct 19;10(10):CD010893. doi: 10.1002/14651858.CD010893.pub3.
6
Evidence-based recommendations for the practical management of Familial Mediterranean Fever.基于证据的家族性地中海热实用管理推荐。
Semin Arthritis Rheum. 2013 Dec;43(3):387-91. doi: 10.1016/j.semarthrit.2013.04.011. Epub 2013 Jun 3.
7
Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents.儿童和青少年中对秋水仙碱耐药的家族性地中海热的治疗。
Rheumatol Int. 2015 Oct;35(10):1733-7. doi: 10.1007/s00296-015-3293-2. Epub 2015 May 23.
8
Successful management of colchicine resistant familial Mediterranean fever patients with a standardized canakinumab treatment protocol: a case series and literature review.成功管理对秋水仙碱耐药的家族性地中海热患者的标准化康纳单抗治疗方案:病例系列和文献复习。
Rheumatol Int. 2020 Jan;40(1):161-168. doi: 10.1007/s00296-019-04366-w. Epub 2019 Jul 4.
9
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
10
Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial.托珠单抗用于对秋水仙碱耐药或不耐受的家族性地中海热的疗效和安全性比较:一项研究者发起的、多中心、随机、双盲、安慰剂对照试验的研究方案
Trials. 2018 Dec 29;19(1):715. doi: 10.1186/s13063-018-3105-6.

引用本文的文献

1
Treat-to-target strategies for the management of familial Mediterranean Fever in children.针对儿童家族性地中海热的靶向治疗策略。
Pediatr Rheumatol Online J. 2023 Sep 26;21(1):108. doi: 10.1186/s12969-023-00875-y.

本文引用的文献

1
Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial.Canakinumab 在秋水仙碱抵抗的家族性地中海热患者中的长期疗效和安全性:来自随机 III 期 CLUSTER 试验的结果。
Ann Rheum Dis. 2020 Oct;79(10):1362-1369. doi: 10.1136/annrheumdis-2020-217419. Epub 2020 Jun 22.
2
A systematic literature review of efficacy, effectiveness and safety of biologic therapies for treatment of familial Mediterranean fever.生物疗法治疗家族性地中海热的疗效、有效性和安全性的系统文献综述。
Rheumatology (Oxford). 2020 Oct 1;59(10):2711-2724. doi: 10.1093/rheumatology/keaa205.
3
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.
心梗后小剂量秋水仙碱的疗效和安全性。
N Engl J Med. 2019 Dec 26;381(26):2497-2505. doi: 10.1056/NEJMoa1912388. Epub 2019 Nov 16.
4
Comorbidities in familial Mediterranean fever: analysis of 2000 genetically confirmed patients.家族性地中海热的合并症:2000 例基因确诊患者的分析。
Rheumatology (Oxford). 2020 Jun 1;59(6):1372-1380. doi: 10.1093/rheumatology/kez410.
5
[Evidence-based treatment recommendations for familial Mediterranean fever : A joint statement by the Society for Pediatric and Adolescent Rheumatology and the German Society for Rheumatology].[家族性地中海热的循证治疗建议:儿科与青少年风湿病学会和德国风湿病学会联合声明]
Z Rheumatol. 2019 Feb;78(1):91-101. doi: 10.1007/s00393-018-0588-1.
6
Update on the epidemiology and disease outcome of Familial Mediterranean fever.家族性地中海热的流行病学和疾病转归更新。
Best Pract Res Clin Rheumatol. 2018 Apr;32(2):254-260. doi: 10.1016/j.berh.2018.09.003. Epub 2018 Sep 29.
7
Which definition should be used to determine colchicine resistance among patients with familial Mediterranean fever?对于家族性地中海热患者,应该使用哪种定义来确定秋水仙碱耐药性?
Clin Exp Rheumatol. 2018 Nov-Dec;36(6 Suppl 115):97-102. Epub 2018 Nov 12.
8
Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.卡那奴单抗治疗自身炎症性反复发作性发热综合征。
N Engl J Med. 2018 May 17;378(20):1908-1919. doi: 10.1056/NEJMoa1706314.
9
Update on colchicine, 2017.2017 年秋水仙碱研究进展。
Rheumatology (Oxford). 2018 Jan 1;57(suppl_1):i4-i11. doi: 10.1093/rheumatology/kex453.
10
Overview of the IL-1 family in innate inflammation and acquired immunity.IL-1 家族在天然免疫和获得性免疫中的概述。
Immunol Rev. 2018 Jan;281(1):8-27. doi: 10.1111/imr.12621.